Zevra Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, the company announced a new genetic testing program with GeneDx for patients with suspected Niemann-Pick disease type C.
Zevra Therapeutics, Inc. +1.03%
Zevra Therapeutics, Inc. ZVRA | 10.78 | +1.03% |
Zevra Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, the company announced a new genetic testing program with GeneDx for patients with suspected Niemann-Pick disease type C.
